avapro has been researched along with Chronic Kidney Diseases in 9 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Short treatment duration, lower pretreatment proteinuria than expected." | 2.90 | Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Total effective rate in treating proteinuria in high-dose group was 72." | 2.76 | [The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease]. ( Chen, XD; Li, X; Li, ZX, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| James, M | 1 |
| Manns, B | 1 |
| Ruggiero, B | 1 |
| Trillini, M | 1 |
| Tartaglione, L | 1 |
| Rotondi, S | 1 |
| Perticucci, E | 1 |
| Tripepi, R | 1 |
| Aparicio, C | 1 |
| Lecchi, V | 1 |
| Perna, A | 1 |
| Peraro, F | 1 |
| Villa, D | 1 |
| Ferrari, S | 1 |
| Cannata, A | 1 |
| Mazzaferro, S | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Bellasi, A | 1 |
| Cozzolino, M | 1 |
| Remuzzi, G | 1 |
| Ruggenenti, P | 1 |
| Kohan, DE | 1 |
| Peters, CD | 2 |
| Kjærgaard, KD | 1 |
| Jespersen, B | 2 |
| Christensen, KL | 1 |
| Jensen, JD | 2 |
| Kjaergaard, KD | 1 |
| Tietze, IN | 1 |
| Madsen, JK | 1 |
| Pedersen, BB | 1 |
| Novosel, MK | 1 |
| Laursen, KS | 1 |
| Bibby, BM | 1 |
| Strandhave, C | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Hayashi, K | 2 |
| Sasamura, H | 1 |
| Nakamura, M | 1 |
| Sakamaki, Y | 1 |
| Azegami, T | 1 |
| Oguchi, H | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Harada, M | 1 |
| Kamijo, Y | 1 |
| Nakajima, T | 1 |
| Hashimoto, K | 1 |
| Yamada, Y | 1 |
| Shimojo, H | 1 |
| Gonzalez, FJ | 1 |
| Aoyama, T | 1 |
| Li, X | 1 |
| Chen, XD | 1 |
| Li, ZX | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment[NCT01968759] | Phase 2 | 53 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study[NCT00791830] | Phase 3 | 82 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for avapro and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chelating Agents; Cross-Over Studies; Drug Monitoring; Dru | 2019 |
Renal and cardiovascular effects of irbesartan in dialysis patients--a randomized controlled trial protocol (SAFIR study).
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Hemodynamics; Huma | 2013 |
Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Biphenyl Compounds; Disease Progression | 2014 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Dru | 2017 |
[The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].
Topics: Adult; Aged; Biphenyl Compounds; Female; Humans; Irbesartan; Male; Middle Aged; Prospective Studies; | 2011 |
3 other studies available for avapro and Chronic Kidney Diseases
| Article | Year |
|---|---|
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Humans; Irbesartan; | 2018 |
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2015 |
Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan.
Topics: Animals; Biphenyl Compounds; Humans; Irbesartan; Kidney; Male; Mice; Mice, Knockout; Oxidative Stres | 2016 |